Total Payments
$1,568
2024 Payments
$288.27
Companies
17
Transactions
98
Medicare Patients
1,261
Medicare Billing
$256,017
Payment Breakdown by Category
Food & Beverage$1,552 (99.0%)
Education$16.24 (1.0%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,552 | 97 | 99.0% |
| Education | $16.24 | 1 | 1.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Melinta Therapeutics, LLC | $290.35 | 20 | $0 (2024) |
| ABBVIE INC. | $289.61 | 18 | $0 (2024) |
| Allergan Inc. | $222.15 | 13 | $0 (2019) |
| Insmed, Inc. | $187.79 | 12 | $0 (2023) |
| Gilead Sciences, Inc. | $166.46 | 10 | $0 (2024) |
| Merck Sharp & Dohme LLC | $114.76 | 7 | $0 (2023) |
| Philips Electronics North America Corporation | $70.96 | 4 | $0 (2022) |
| Ferring Pharmaceuticals Inc. | $52.28 | 3 | $0 (2023) |
| Astellas Pharma US Inc | $33.38 | 2 | $0 (2018) |
| AstraZeneca Pharmaceuticals LP | $25.64 | 2 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $288.27 | 17 | Melinta Therapeutics, LLC ($144.56) |
| 2023 | $211.31 | 13 | AbbVie Inc. ($78.31) |
| 2022 | $278.82 | 17 | ABBVIE INC. ($117.42) |
| 2021 | $105.47 | 7 | Insmed, Inc. ($49.88) |
| 2020 | $83.87 | 6 | Melinta Therapeutics, LLC ($30.14) |
| 2019 | $368.45 | 25 | Gilead Sciences, Inc. ($71.91) |
| 2018 | $103.19 | 6 | Allergan Inc. ($89.59) |
| 2017 | $128.91 | 7 | Allergan Inc. ($109.13) |
All Payment Transactions
98 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | Melinta Therapeutics, LLC | Rezzayo (Drug), Kimyrsa, Orbactiv | Food and Beverage | In-kind items and services | $23.29 | General |
| Category: ANTIFUNGALS | ||||||
| 10/31/2024 | Melinta Therapeutics, LLC | Rezzayo (Drug), Kimyrsa, Orbactiv | Food and Beverage | In-kind items and services | $16.68 | General |
| Category: ANTIFUNGALS | ||||||
| 10/01/2024 | Melinta Therapeutics, LLC | Rezzayo (Drug), Kimyrsa, Orbactiv | Food and Beverage | In-kind items and services | $7.48 | General |
| Category: ANTIFUNGALS | ||||||
| 08/22/2024 | Melinta Therapeutics, LLC | Rezzayo (Drug), Orbactiv, Kimyrsa | Food and Beverage | In-kind items and services | $9.66 | General |
| Category: ANTIFUNGALS | ||||||
| 08/01/2024 | Melinta Therapeutics, LLC | Rezzayo (Drug), Kimyrsa, Orbactiv | Food and Beverage | In-kind items and services | $10.10 | General |
| Category: ANTIFUNGALS | ||||||
| 07/25/2024 | ABBVIE INC. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $13.88 | General |
| Category: ANTI-INFECTIVE | ||||||
| 07/18/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $15.03 | General |
| 06/11/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $32.47 | General |
| Category: VIROLOGY | ||||||
| 06/08/2024 | Melinta Therapeutics, LLC | Rezzayo (Drug), Kimyrsa, Orbactiv | Food and Beverage | In-kind items and services | $13.36 | General |
| Category: ANTIFUNGALS | ||||||
| 05/16/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $29.50 | General |
| 05/09/2024 | Melinta Therapeutics, LLC | Rezzayo (Drug) | Food and Beverage | In-kind items and services | $15.71 | General |
| Category: ANTIFUNGALS | ||||||
| 04/11/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $16.50 | General |
| 04/06/2024 | Melinta Therapeutics, LLC | Rezzayo (Drug), Kimyrsa, Orbactiv | Food and Beverage | In-kind items and services | $16.13 | General |
| Category: ANTIFUNGALS | ||||||
| 03/07/2024 | ABBVIE INC. | DALVANCE (Drug), AVYCAZ, TEFLARO | Food and Beverage | In-kind items and services | $13.66 | General |
| Category: ANTI-INFECTIVE | ||||||
| 02/23/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $22.67 | General |
| Category: VIROLOGY | ||||||
| 02/15/2024 | Melinta Therapeutics, LLC | Rezzayo (Drug), Vabomere, Orbactiv | Food and Beverage | In-kind items and services | $12.80 | General |
| Category: ANTIFUNGALS | ||||||
| 01/18/2024 | Melinta Therapeutics, LLC | Rezzayo (Drug), Vabomere, Kimyrsa | Food and Beverage | In-kind items and services | $19.35 | General |
| Category: ANTIFUNGALS | ||||||
| 12/08/2023 | Melinta Therapeutics, LLC | Rezzayo (Drug), Kimyrsa, Vabomere | Food and Beverage | In-kind items and services | $16.28 | General |
| Category: ANTIFUNGALS | ||||||
| 10/26/2023 | AbbVie Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $15.36 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/05/2023 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $17.18 | General |
| Category: Respiratory | ||||||
| 09/14/2023 | Gilead Sciences, Inc. | Veklury (Drug) | Food and Beverage | In-kind items and services | $18.13 | General |
| Category: COVID-19 | ||||||
| 08/17/2023 | Melinta Therapeutics, LLC | Rezzayo (Drug), Vabomere, Kimyrsa | Food and Beverage | In-kind items and services | $13.66 | General |
| Category: ANTIFUNGALS | ||||||
| 07/07/2023 | Ferring Pharmaceuticals Inc. | REBYOTA (Biological) | Food and Beverage | In-kind items and services | $15.81 | General |
| Category: GASTROENTEROLOGY | ||||||
| 06/29/2023 | AbbVie Inc. | TEFLARO (Drug) | Food and Beverage | In-kind items and services | $13.39 | General |
| Category: ANTI-INFECTIVE | ||||||
| 06/22/2023 | Merck Sharp & Dohme LLC | DIFICID (Drug), ZERBAXA, RECARBRIO | Food and Beverage | In-kind items and services | $13.63 | General |
| Category: INFECTIOUS DISEASE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 330 | 551 | $120,845 | $50,321 |
| 2022 | 6 | 274 | 565 | $141,447 | $57,058 |
| 2021 | 8 | 298 | 566 | $143,163 | $57,982 |
| 2020 | 8 | 359 | 838 | $221,824 | $90,657 |
Total Patients
1,261
Total Services
2,520
Medicare Billing
$256,017
Procedure Codes
29
All Medicare Procedures & Services
29 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 80 | 97 | $31,428 | $13,270 | 42.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 61 | 112 | $24,192 | $10,145 | 41.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 64 | 155 | $22,475 | $9,770 | 43.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 52 | 84 | $15,540 | $5,409 | 34.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 32 | 57 | $10,944 | $5,405 | 49.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 30 | 30 | $8,250 | $3,578 | 43.4% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 11 | 16 | $8,016 | $2,743 | 34.2% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 22 | 94 | $47,094 | $16,517 | 35.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 65 | 211 | $30,595 | $11,906 | 38.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 65 | 116 | $25,056 | $11,309 | 45.1% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 61 | 68 | $22,032 | $10,684 | 48.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 29 | 29 | $7,975 | $3,579 | 44.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 32 | 47 | $8,695 | $3,062 | 35.2% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2021 | 28 | 100 | $50,100 | $17,796 | 35.5% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 72 | 77 | $24,933 | $12,300 | 49.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 63 | 185 | $26,825 | $10,467 | 39.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 57 | 89 | $16,465 | $6,032 | 36.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 39 | 53 | $11,448 | $5,338 | 46.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 12 | 32 | $6,108 | $2,642 | 43.3% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 16 | 16 | $4,400 | $1,992 | 45.3% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 11 | 14 | $2,884 | $1,416 | 49.1% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2020 | 56 | 241 | $114,957 | $43,936 | 38.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 77 | 231 | $31,885 | $13,534 | 42.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 31 | 110 | $20,130 | $9,357 | 46.5% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 40 | 41 | $12,684 | $6,753 | 53.2% |
About Dr. John Bolden, M.D
Dr. John Bolden, M.D is a Infectious Disease healthcare provider based in Morris, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/18/2007. The National Provider Identifier (NPI) number assigned to this provider is 1073666707.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Bolden, M.D has received a total of $1,568 in payments from pharmaceutical and medical device companies, with $288.27 received in 2024. These payments were reported across 98 transactions from 17 companies. The most common payment nature is "Food and Beverage" ($1,552).
As a Medicare-enrolled provider, Bolden has provided services to 1,261 Medicare beneficiaries, totaling 2,520 services with total Medicare billing of $256,017. Data is available for 4 years (2020–2023), covering 29 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Morris, IL
- Active Since 01/18/2007
- Last Updated 04/28/2020
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1073666707
Products in Payments
- DALVANCE (Drug) $188.81
- Rezzayo (Drug) $174.50
- Arikayce (Drug) $169.94
- MAVYRET (Drug) $136.20
- TEFLARO (Drug) $125.43
- PIFELTRO (Drug) $70.88
- AVYCAZ (Drug) $61.32
- Vabomere (Drug) $58.04
- Orbactiv (Drug) $57.81
- inCourage (Device) $46.34
- REBYOTA (Biological) $34.39
- DIFICID (Drug) $28.47
- SYMBICORT (Drug) $25.64
- (8874) inCourage (Device) $24.62
- NUZYRA (Drug) $20.00
- Cresemba (Drug) $19.78
- Veklury (Drug) $18.13
- ENTRESTO (Drug) $17.88
- TRELEGY ELLIPTA (Drug) $16.91
- Aimovig (Biological) $16.72
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.